Data from a six-year multicentre clinical trial confirms that CooperVision MiSight 1 day contact lenses provide myopia control for nearly all children, according to a new peer review paper.
In the longest-running soft contact lens study among children, 90% of myopic eyes responded to MiSight 1 day wear with a proportional treatment effect, meaning that younger and faster-progressing children receive the maximum benefit.
Evidence also indicated a sustained slowing of eye growth with no loss of effectiveness over time.
These findings are published in the March 2022 edition of Optometry and Vision Science, the peer review journal of the American Academy of Optometry. The paper, ‘Long-Term Effect of Dual-Focus Contact Lenses on Myopia Progression in Children: A 6-year Multicenter Clinical Trial’, is now available via Open Access.
The peer-reviewed six-year paper complements additional CooperVision research demonstrating that the lens slows the rate of myopia progression by half at all observed ages. The data also support that it’s never too late to start treatment, as the lens halves myopia progression in older children as well.
Mr Paul Chamberlain, the study’s principal investigator and CooperVision director of research programs, said the results instil confidence.
“Myopia is a disease that progresses over many years, so demonstrating sustained efficacy is critical,” he said.
“Eyecare professionals can prescribe MiSight 1 day with confidence knowing that the majority of children respond to treatment which lasts.”
The MiSight 1 day study is the world’s longest running soft contact lens clinical trial for myopia management.
This new paper joins a growing body of peer-reviewed research stemming from the CooperVision MiSight 1 day study including Ocular Health of Children Wearing Daily Disposable Contact Lenses Over a 6-year Period (Woods J, et al.) and Axial Length Targets for Myopia Control (Chamberlain P, et al.), as well as the recent Garland W Clay Award winner, A 3-year Randomized Clinical Trial of MiSight Lenses for Myopia Control (Chamberlain P, et al.).